Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Freundlich B, Lange E, Rudwaleit M, Sieper J.

Semin Arthritis Rheum. 2016 Feb;45(4):404-10. doi: 10.1016/j.semarthrit.2015.08.005. Epub 2015 Sep 4.

PMID:
26519007
2.

Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Lange E, Freundlich B, Rudwaleit M, Sieper J.

Rheumatology (Oxford). 2015 Feb;54(2):257-61. doi: 10.1093/rheumatology/keu263. Epub 2014 Aug 19.

PMID:
25140041
4.

Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiß A, Buß B, Freundlich B, Lange E, Alten R, Rudwaleit M, Sieper J.

J Rheumatol. 2014 Oct;41(10):2034-40. doi: 10.3899/jrheum.140056. Epub 2014 Jul 15.

PMID:
25028375
5.

Response to: 'is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?' by Fleishman and Yazici.

Schiff MH, Jaffe JS, Freundlich B.

Ann Rheum Dis. 2014 Sep;73(9):e55. doi: 10.1136/annrheumdis-2014-205938. Epub 2014 Jun 24. No abstract available.

PMID:
24962874
6.

New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.

Schiff M, Jaffe J, Freundlich B, Madsen P.

Expert Rev Med Devices. 2014 Sep;11(5):447-55. doi: 10.1586/17434440.2014.929492. Epub 2014 Jun 17. Review.

PMID:
24934630
8.

Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.

Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2013 Jun;72(6):823-5. doi: 10.1136/annrheumdis-2012-202389. Epub 2012 Nov 21.

PMID:
23172749
9.

Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI.

Althoff CE, Sieper J, Song IH, Haibel H, Weiß A, Diekhoff T, Rudwaleit M, Freundlich B, Hamm B, Hermann KG.

Ann Rheum Dis. 2013 Jun;72(6):967-73. doi: 10.1136/annrheumdis-2012-201545. Epub 2012 Jun 26.

PMID:
22736088
10.

Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial.

Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, Khandker R, Nab H, Freundlich B, Koenig A.

Int J Rheum Dis. 2012 Apr;15(2):188-96. doi: 10.1111/j.1756-185X.2011.01680.x. Epub 2011 Oct 28.

PMID:
22462423
11.

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, Weiß A, Djacenko S, Burmester GR, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2012 Jul;71(7):1212-5. doi: 10.1136/annrheumdis-2011-201010. Epub 2012 Mar 22.

PMID:
22440819
12.

Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.

Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS.

Ann Rheum Dis. 2012 Jun;71(6):989-92. doi: 10.1136/annrheumdis-2011-201066. Epub 2012 Mar 8.

PMID:
22402142
13.

Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement.

Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, Koenig AS.

J Rheumatol. 2012 Apr;39(4):836-40. doi: 10.3899/jrheum.110885. Epub 2012 Feb 15.

PMID:
22337244
14.

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).

Strohal R, Puig L, Chouela E, Tsai TF, Melin J, Freundlich B, Molta CT, Fuiman J, Pedersen R, Robertson D.

J Dermatolog Treat. 2013 Jun;24(3):169-78. doi: 10.3109/09546634.2012.658015. Epub 2012 Feb 23.

PMID:
22251226
15.

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.

Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1436-43. doi: 10.1111/j.1468-3083.2011.04308.x. Epub 2011 Oct 31.

PMID:
22035157
16.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH; American Society of Clinical Oncology.

J Clin Oncol. 2011 Nov 1;29(31):4189-98. doi: 10.1200/JCO.2010.34.4614. Epub 2011 Sep 26. Review. Erratum in: J Clin Oncol. 2014 Jun 1;32(19):2117. Dosage error in article text.

17.

Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis?

Zhang W, Sun H, Emery P, Sato R, Singh A, Freundlich B, Anis AH.

Rheumatology (Oxford). 2012 Feb;51(2):270-4. doi: 10.1093/rheumatology/ker189. Epub 2011 Jun 29.

PMID:
21719418
18.

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.

Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B.

Arthritis Rheum. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223.

19.

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48.

Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Weiss A, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2011 Jul;70(7):1257-63. doi: 10.1136/ard.2010.147033. Epub 2011 May 8.

20.

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial.

Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, Krause A, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2011 Apr;70(4):590-6. doi: 10.1136/ard.2010.139667. Erratum in: Ann Rheum Dis. 2011 Jul;70(7):1350. Althoff, Ce [corrected to Althoff, C E].

21.

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.

Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1):26-34. Epub 2011 Feb 23.

PMID:
21345289
22.

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M.

Rheumatol Int. 2012 Jun;32(6):1617-24. doi: 10.1007/s00296-011-1807-0. Epub 2011 Feb 18.

23.

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M.

Rheumatol Int. 2012 Jun;32(6):1511-9. doi: 10.1007/s00296-010-1784-8. Epub 2011 Feb 16.

24.

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M.

Mod Rheumatol. 2011 Aug;21(4):343-51. doi: 10.1007/s10165-010-0406-3. Epub 2011 Jan 25.

25.

Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate.

Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW.

J Rheumatol. 2011 Feb;38(2):242-6. doi: 10.3899/jrheum.091446. Epub 2010 Nov 15.

PMID:
21078715
26.

Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.

Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A.

Rheumatology (Oxford). 2011 Feb;50(2):401-9. doi: 10.1093/rheumatology/keq327. Epub 2010 Nov 8.

PMID:
21059675
27.

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.

Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B.

J Eur Acad Dermatol Venereol. 2011 May;25(5):559-64. doi: 10.1111/j.1468-3083.2010.03838.x. Epub 2010 Sep 14.

PMID:
20840349
28.

Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.

Martín-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, Koenig AS, Freundlich B.

Clin Exp Rheumatol. 2010 Mar-Apr;28(2):238-45. Epub 2010 May 13.

PMID:
20483046
29.

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.

Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, Freundlich B; Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group.

Arthritis Rheum. 2010 Mar;62(3):674-82. doi: 10.1002/art.27268. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

30.

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.

Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.

Eur J Dermatol. 2010 May-Jun;20(3):323-8. doi: 10.1684/ejd.2010.0911. Epub 2010 Feb 25.

PMID:
20185386
31.

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B.

BMJ. 2010 Feb 2;340:c147. doi: 10.1136/bmj.c147.

PMID:
20124563
32.

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study.

Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, Sato R.

Rheumatology (Oxford). 2009 Oct;48(10):1283-9. doi: 10.1093/rheumatology/kep239. Epub 2009 Aug 18.

PMID:
19690125
33.

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept.

Ortonne JP, Taïeb A, Ormerod AD, Robertson D, Foehl J, Pedersen R, Molta C, Freundlich B.

Br J Dermatol. 2009 Nov;161(5):1190-5. doi: 10.1111/j.1365-2133.2009.09238.x. Epub 2009 May 21.

PMID:
19566665
34.

Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.

Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, Freundlich B.

Ann Rheum Dis. 2010 Jan;69(1):226-9. doi: 10.1136/ard.2008.103192.

PMID:
19465402
35.

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.

Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M.

J Rheumatol. 2009 May;36(5):898-906. doi: 10.3899/jrheum.080791. Epub 2009 Mar 30.

36.

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R.

Ann Rheum Dis. 2010 Jan;69(1):222-5. doi: 10.1136/ard.2008.102509. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19293160
37.

Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.

Keystone E, Freundlich B, Schiff M, Li J, Hooper M.

J Rheumatol. 2009 Mar;36(3):522-31. doi: 10.3899/jrheum.080663. Epub 2009 Feb 17.

PMID:
19228659
38.

Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.

van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, Robertson D, Chang D, Koenig A, Freundlich B; Etanercept Study Investigators.

Ann Rheum Dis. 2009 Jul;68(7):1113-8. doi: 10.1136/ard.2008.094375. Epub 2008 Aug 21.

39.

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B.

Lancet. 2008 Aug 2;372(9636):375-82. doi: 10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.

PMID:
18635256
40.

Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.

Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M.

Ann Rheum Dis. 2008 Oct;67(10):1444-7. doi: 10.1136/ard.2008.094524. Epub 2008 Jun 5.

41.

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.

Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Freundlich B, Stevens SR.

Value Health. 2008 May-Jun;11(3):400-7. doi: 10.1111/j.1524-4733.2007.00251.x.

42.

The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.

van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ; Etanercept Study 400 Investigators.

Ann Rheum Dis. 2008 Feb;67(2):182-8. Epub 2007 Aug 29.

PMID:
17728331
43.

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A; ADORE Study Investigators.

Ann Rheum Dis. 2008 Aug;67(8):1104-10. Epub 2007 Jul 31.

PMID:
17666447
44.

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.

J Am Acad Dermatol. 2007 Apr;56(4):598-603. Epub 2006 Nov 17.

PMID:
17113190
45.

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.

van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D; Add Enbrel or Replace Methotrexate Study Investigators.

Ann Rheum Dis. 2006 Nov;65(11):1478-83. Epub 2006 Feb 7.

46.

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S.

Ann Rheum Dis. 2006 Mar;65(3):328-34. Epub 2005 Aug 3.

47.

Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.

Wolfe F, Freundlich B, Straus WL.

J Rheumatol. 2003 Jan;30(1):36-40.

PMID:
12508387
48.

Anterior knee pain: a common problem with little data.

Freundlich B.

J Clin Rheumatol. 1999 Apr;5(2):47-8. No abstract available.

PMID:
19078355
49.

Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings.

Armstrong C, Lewis T, D'Esposito M, Freundlich B.

J Neurol Neurosurg Psychiatry. 1997 Nov;63(5):633-41.

50.

Supplemental Content

Loading ...
Support Center